Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer. A Phase II trial of the Southwest Oncology Group.
Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer. A Phase II trial of the Southwest Oncology Group.
复制标题
甲基乙二醛双脒腙（甲基-GAG，MGBG）治疗晚期乳腺癌。
DOI：
10.1007/bf00173789
复制
发表时间：
1984
影响因子：
3.4
通讯作者：
Costanzi,JJ
中科院分区：
文献类型：
--
作者：
Knight3rd,WA;O'Bryan,RM;Samal,B;Costanzi,JJ
西南肿瘤学小组在转移性乳腺癌患者中每周评估甲基-GAG。在72例完全和部分可评价的患者中，观察到1例完全缓解和4例部分缓解。毒性与该化合物的其他试验相似，但血小板减少症除外，血小板减少症更频繁和严重，可能与肿瘤浸润骨髓有关。此外，1例患者在甲基-GAG后发生回忆性皮炎。此前尚未报道过该化合物的这种毒性。甲基-GAG在该剂量和方案下在接受过大量预治疗的乳腺癌患者中具有最小活性。
The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with metastatic breast cancer. Among 72 fully and partial evaluable patients, one complete and four partial responses were seen. Toxicity was similar to other trials with this compound except for thrombocytopenia which was more frequent and severe and probably related to tumor infiltrating marrow. In addition, one patient experienced recall dermatitis following methyl-GAG. This toxicity has not been previously reported with this compound. Methyl-GAG has minimal activity at this dose and schedule among heavily pretreated patients with breast cancer.